Phase 3 topline — Felzartamab
Biogen Inc. · NASDAQ · $33.1B market cap
Q2 2027
Bias Score
P(positive outcome)
Forecast move
Date confidence
45%
Company guidance for a period, e.g. 2H 2026.
What this event is
A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN)
- Drug
- Felzartamab
- Mechanism
- —
- Indication
- Immunoglobulin A Nephropathy (IgAN)
- Primary endpoint
- Percent Change From Baseline in Proteinuria as Measured by the Urine Protein: Creatinine Ratio (UPCR)
- Enrollment
- 454
- Source
- ClinicalTrials.gov
Full dossier
Trial design and what the registration does and does not record, the primary endpoint and how it is assessed, where the date comes from and how firm it is, and the balance-sheet position going into the print.
Aperture unlocks the full dossier on every event — trial design, endpoint, date provenance, balance sheet.
See pricingHow the model got here
Aperture unlocks the model's written rationale for each score.
See pricingFeature attribution
Aperture unlocks per-event feature attribution from the model.
See pricingTwo-sided forecast
Aperture unlocks the calibrated probability and Bias Score for every event.
See pricingCompany
- Market cap
- $33.1B
- Cash
- $2.9B
- Runway
- —
- Approved products
- 0
Research, not advice. Aperture is not a registered investment adviser or broker-dealer and does not provide personalised recommendations. Nothing here is sized to your circumstances. Trial details come from the sponsor's own ClinicalTrials.gov registration, which sponsors revise; the date is the registered primary completion date, not a commitment.